News | November 18, 2007

Flourescence Spectroscopy Used to Detect CAD

November 19, 2007 – Prescient Medical Inc. has acquired Time Resolved Light Induced Fluorescence Spectroscopy (TR-LIFS) technology designed for early detection, diagnosis and quantification of coronary artery disease.

TR-LIFS exploits the phenomenon that bi-products of metabolic activity behave differently than surrounding tissue. In TR-LIFS, a short light pulse (picoseconds) is used to excite the tissue, and then the resulting light that emanates from the tissue is monitored over a brief time span (several nanoseconds).

The company expects the technology to be used to identify coronary plaques before a major heart attack can occur. TR-LIFS is reportedly well suited to detecting macrophages, and Prescient Medical plans to integrate TR-LIFS technology into its vPredict Optical Catheter System, an intravascular diagnostic instrument that is currently in development.

For more information:

Overlay Init